In vivo REsponse evaluation of colorectal liver metastases during systemic therapy using optical SPECTroscopy techniques

1. Patients with unresectable colorectal liver metastases;

2. The liver lesions are safely accessible according to an intervention-radiologist;

3. First line systemic treatment with Capacitabin and Oxaliplatin or FOLFOX, both with or without biologicals;

4. Written informed consent >18y.

Breast Specific Inclusion criteria
- Breast patients with a BIRADS score 4 or 5

1. Patients with suspected sensitivity to light; e.g. patients who have had photodynamic therapy;

2. Patients with bleeding disorders (such as hemophilia) or bleeding complications from biopsies, dental procedures or surgery;

3. Patients using any anti-coagulant medication at the time of biopsy: all aspirin derivatives, coumarines, platelet function inhibitors, heparins (including LMWHs) and oral factor Xa inhibitors are not allowed, unless medication can either be safely stopped or counteracted;

4. Patients with indequate hematology and coagulation status as measured by:

* Hb < 6.0 mmol/L;

* Platelet count < 100 x 109/L;

* PT < 1.5 x Upper limit of normal (ULN);

* APTT < 1.5 x ULN;

* PT-INR < 1.5 on the day of biopsy in patients using coumarines;

* Patients known with contraindications for lidocaine (or its derivatives).

Breast Specific Exclusion criteria
- Patients who have a history of breast cancer and/or who have received prior chemotherapy, endocrine therapy, or radiation therapy

- Patients who have breast implants

- Patients needing a stereotactic breast biopsy (i.e. non palpable-, ultrasound opaque lesions).